In this article, a case of decubitus ulcer infection caused by an extended-spectrum β-lactamase-producing Proteus mirabilis strain, successfully treated with oral amoxicillin-clavulanate (1-month therapy) is described. This article focuses on diffusion and clinical effect of extended-spectrum β-lactamases-producing Proteus mirabilis on treatment of gram negative lower extremity infections.
D'Azevedo PA , Gonçalves ALS , Musskopf MI, Ramos CG, Dias CAG.Laboratory tests in the detection of extended-spectrum β-lactamase production: National Committee for Clinical Laboratory Standards (NCCLS) screening test, the E-test, the double disk confirmatory test, and cefoxitin susceptibility testing. Braz J Infect Dis. 2004;8:372-377.
2.
Jarlier V., Nicolas MH, Fournier G., Philippon A.Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis1988 ;10:867-868.
3.
Endimiani A. , Luzzaro F., Brigante G., et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2005;49:2598-2605.
4.
Nagano N., Shibata N., Saitou Y., Nagano Y., Arakawa Y.Nosocomial outbreak of infections by Proteus mirabilis that produces extended-spectrum CTX-M-2 type beta-lactamase. J Clin Microb. 2003;41:5530-5536.
5.
Bonnet R., De Champs C., Sirot D., Chanal C., Labia R., Sirot J.Diversity of TEM mutants in Proteus mirabilis. Antimicrob Agents Chemother. 1999;43:2671-2677.
6.
Chanal C., Bonnet R., De Champs C., Sirot D., Labia R., Sirot J.Prevalence of beta-lactamases among 1.072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital. Antimicrob Agents Chemother . 2000; 44:1930-1935.
7.
De Champs C. , Monne C., Bonnet R., et al. New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates. Antimicrob Agents Chemother. 2001;45: 1278-1280.
Pitout JDD , Thomson KS, Hanson ND, Ehrhardt AF, Moland ES, Sanders CCBeta-lactamases responsible for resistance to extended-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Antimicrob Agents Chemother. 1998;42:1350-1354.
10.
Pagani L., Migliavacca R., Pallecchi L., et al. Emerging extended-spectrum beta-lactamases in Proteus mirabilis . J Clin Microb. 2002;40:1549-1552.
11.
Palzkill T. , Thomson KS, Sanders CC, Moland ES, Huang W., Milligan TWNew variant of TEM-10 beta-lactamase gene produced by a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother. 1995;39: 1199-1200.
